Goodwin Procter advised DJS Antibodies on the deal. AbbVie (NYSE: ABBV) announced the acquisition of DJS Antibodies Ltd (“DJS”), a privately-held UK-based biotechnology company dedicated to discovering...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here